Internal Medicine

For rare and inherited kidney diseases, genetic testing is solving the clinical trial recruitment crisis and reshaping how precision therapies get to patients.

The new DMF gives developers a faster, simpler path to advance their cell therapy programs using trusted, clinical-grade starting materials.

Insilico’s Phase 2a trial of an AI-designed therapy marks a milestone in data-driven drug development.

Point-of-care tests that detect biomarkers from menstrual blood can enable broader access to disease monitoring and diagnosis.

Expanded high-value end-to-end solution positions business for rapid growth in multi-billion dollar functional GI market

A new CRISPR center for kids, Trump threatens 200 percent tariffs on foreign-made drugs, the first malaria treatment for babies, and more led this week’s news. 

Explore how a rare kidney disease trial achieved faster patient enrollment with data-informed strategies and collaborative partnerships.

Two new FDA approvals and promising clinical trial results for drugs to treat diabetes and lung cancer, and more led the news this week.

Using artificial intelligence and machine learning, a team of researchers engineered an enzyme to degrade toxic PFAS molecules — and they’re only in high school.

A blood test for organ rejection, another death related to gene therapy for Duchenne muscular dystrophy, a setback for AbbVie, and more led the news this week.

Clinical trials rigorously test treatments to further scientific knowledge and benefit patients. Neither happens if the results are never published.

Home-based healthcare is emerging as a scalable, cost-effective solution to rising systemic pressures, offering resilience in the face of economic, geopolitical, and operational uncertainty.